RTTNews | Jan 19, 2022 07:28AM EST

07:27 Wednesday, January 19, 2022 (RTTNews.com) - Regeneron Pharmaceuticals Inc. (REGN) said Wednesday that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with chemotherapy as first-line treatment in advanced non-small cell lung cancer or NSCLC.

The target action date for the FDA decision is September 19, 2022.

In 2021, Libtayo was approved in the U.S. and European Union as first-line monotherapy treatment for adult patients with advanced NSCLC whose tumors have high PD-L1 expression (tumor proportion score 50%), as determined by an FDA-approved test.

Libtayo, which was invented using Regeneron's proprietary VelocImmune technology, is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.

Read the original article on RTTNews ( https://www.rttnews.com/3255901/regn-fda-accepts-for-review-libtayo-chemotherapy-combination-for-advanced-lung-cancer-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved